scholarly journals Dosymmetric estimates of 99mTc (MAA) and 133Xe in newborn lungs using Cristy-Eckerman / Segars representations

MOMENTO ◽  
2022 ◽  
pp. 54-65
Author(s):  
Marcial Vasquez-Arteaga ◽  
Héctor Vega-Carrillo ◽  
Gustavo Montalvo-Soberon ◽  
Juan Rivera-Vásquez ◽  
Pedro Jaramillo-Arica ◽  
...  

Using the Cristy-Eckerman (C-E) / Segars anatomical representations and the MIRD formalism, the Absorbed doses in lungs of newborn patients scanned with radiopharmaceuticals 133Xe (ventilation) and 99mTc (MAA) (perfusion) are estimated. These representations are phantoms used in Monte Carlo calculations to determine specific absorbed fractions, which, associated with the pharmaceutical residence time, determine the absorbed dose. Concerns about the dosimetric impact of using these ventilation / perfusion agents, as well as the use of different phantoms, were explored in newborn patients. When the lungs were scanned with 99mTc (MAA), the relative difference in total dose between the C-E / Segars anatomical representations was 1.0%. When the lungs were scanned with 133Xe, the relative difference in total dose between the anthropomorphic representations of C-E / Segars was 0.5%. Regardless of the radiopharmaceutical used for the pulmonary studies of a newborn patient, the substitution of the C-E representation for that of Segars does not reflect very significant changes in the calculation of the absorbed dose in the lungs, where the greatest dosimetric contribution is its self-dose, which is supplied mainly by the electrons produced during the 99mTc and 133Xe decay.

1965 ◽  
Vol 38 (451) ◽  
pp. 541-544 ◽  
Author(s):  
William H. Ellett ◽  
Arthur B. Callahan ◽  
Gordon L. Brownell

1993 ◽  
Vol 20 (2) ◽  
pp. 283-292 ◽  
Author(s):  
Chang-ming Ma ◽  
D. W. O. Rogers ◽  
K. R. Shortt ◽  
C. K. Ross ◽  
A. E. Nahum ◽  
...  

2005 ◽  
Vol 32 (5) ◽  
pp. 1265-1269 ◽  
Author(s):  
A. Sam Beddar ◽  
Tina Marie Briere ◽  
Firas A. Mourtada ◽  
Oleg N. Vassiliev ◽  
H. Helen Liu ◽  
...  

2008 ◽  
Vol 53 (6) ◽  
pp. 1581-1594 ◽  
Author(s):  
Nicholas Koch ◽  
Wayne D Newhauser ◽  
Uwe Titt ◽  
Dan Gombos ◽  
Kevin Coombes ◽  
...  

Author(s):  
Saman Dalvand ◽  
Hossein Rajabi ◽  
Ameneh Omidi ◽  
Etesam Malekzadeh

Purpose: Radiopharmaceutical Therapy (RPT) is one of the effective methods for pain palliation of bone metastases. Bone marrow is a critical organ in bone structure whose absorbed dose should be kept below a certain threshold. The purpose of this study was to calculate and compare absorbed doses of bone-seeking radiopharmaceuticals used in the palliative treatment of bone metastases. Materials and Methods: In this study, the GATE Monte Carlo code was used to simulate a femur bone, which consists of bone marrow, endosteal layer, bone, and soft tissue phantom model. Absorbed doses of the 153Sm-EDTMP, 89SrCl2, 177Lu-EDTMP, 188Re-HEDP, and 223RaCl2 radiopharmaceuticals were calculated in the femur phantom compartments. Results: bone absorbed doses per disintegration from alpha particles of 223RaCl2 is approximately 24 times higher than absorbed doses from beta particles of 89SrCl2. Also, absorbed dose per disintegration from beta particles of 89SrCl2 in the bone is approximately 12, 6 and 1.5 times higher than 177Lu-EDTMP, 153Sm-EDTMP, and 188Re-HEDP, respectively. Moreover, the bone and bone marrow absorbed dose from beta particles of 153Sm-EDTMP is 1.9 times higher than 177Lu-EDTMP. Besides, absorbed dose per disintegration from beta particles of 188Re-HEDP in the bone marrow is approximately 40, 30, 7, and 4 times higher than 223RaCl2, 89SrCl2, 177Lu-EDTMP and 153Sm-EDTMP, respectively. Conclusion: Our results show that 223RaCl2 could be a more efficient radiopharmaceutical for radionuclide therapy of bone metastases. Also, 177Lu-EDTMP, due to low marrow toxicity and comparable bone absorbed dose with 153Sm-EDTMP, can be used for achieving bone pain palliation. Moreover, significantly high bone marrow absorbed dose of 188Re-HEDP should be considered for palliative therapy of metastatic bone patients.


2011 ◽  
Vol 50 (6) ◽  
pp. 973-980 ◽  
Author(s):  
Erik Larsson ◽  
Michael Ljungberg ◽  
Sven-Erik Strand ◽  
Bo-Anders Jönsson

Sign in / Sign up

Export Citation Format

Share Document